Advion’s parent company Bohui Innovation Biotechnology will acquire Interchim group

Advion’s parent company Bohui Innovation Biotechnology will acquire Interchim group

Advion releases Direct Analysis Probe for the compact mass spectrometer (CMS) product line In addition to enhanced product integration, the future combination will offer a single source for all instrumentation, column chromatography, sample prep, and consumables sales. Coupled with complementary geographical and market segment strengths, the eventual combination will drive synergistic growth of both companies. “We are thrilled to combine with Interchim,” said David B. Patteson, who will lead the forthcoming combined Bohui Instrument Group. “Our expanded solution deck and global scale will provide a formidable platform for growth – offering novel media, columns, prep LC, HPLC, flash chromatography, mass spectrometry, sample prep, and much more. Our customers will benefit from an expanded workflow solution portfolio. Interchim’s exceedingly strong Central EU market share and presence, coupled with their dynamic chromatography column business is a perfect commercial fit with Advion’s LC/CMS offering. Together with Interchim, we have built strong relationships which persist to this day.” We are really excited about the perspective of this strategic combination. As a guarantee of a promising future, it represents today for Interchim, its employees, suppliers and partners a perfect fit. The strengths of the two entities, already working together successfully, will be enhanced by this new step and will enable us to reach and develop unparalleled scientific solutions and technological platforms for our customers around the world.” Lionel Boch, Président du Directoire Interchim Customers and industry partners will benefit from this increased solutions portfolio and can expect significant new developments in mass spectrometry, flash and preparative chromatography of small and large molecules over the course of 2020. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More